Balyasny Asset Management
NPCE icon

Balyasny Asset Management’s Neuropace NPCE Stock Holding History

Balyasny Asset Management’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$307K Buy
+23,350
New +$350K ﹤0.01% 2555
2025
Q2 		– Sell
-22,289
Closed -$279K – 3186
2025
Q1 		$274K Buy
+22,289
New +$279K ﹤0.01% 2483
2024
Q2 		– Sell
-26,950
Closed -$356K – 2937
2024
Q1 		$356K Sell
26,950
-206
-0.8% -$2.94K ﹤0.01% 2193
2023
Q4 		$280K Buy
+27,156
New +$217K ﹤0.01% 2189

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Balyasny Asset Management's NPCE Position: Q1 2026 in Review

Balyasny Asset Management opened a new position in Neuropace (NPCE) in Q1 2026: 23,350 shares worth $307K. The stake represents ﹤0.01% of the portfolio and ranks #2555 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in NPCE as recently as Q1 2025.

Balyasny Asset Management first reported a position in NPCE in Q4 2023 and has held it in 4 quarters since. The position peaked at $356K in Q1 2024. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • Balyasny Asset Management held 23,350 shares of Neuropace worth $307K as of Q1 2026.
  • Neuropace was a new Balyasny Asset Management position in Q1 2026.
  • Neuropace made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #2555 holding.
  • Balyasny Asset Management first reported a position in Neuropace in Q4 2023 and has held it in 4 quarters since.
  • Balyasny Asset Management's Neuropace position peaked at $356K in Q1 2024.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.